Suppr超能文献

遗传性球形红细胞增多症的脾切除术:1657例患者回顾及儿科质量指标的应用

Splenectomy in hereditary spherocytosis: Review of 1,657 patients and application of the pediatric quality indicators.

作者信息

Abdullah Fizan, Zhang Yiyi, Camp Melissa, Rossberg Mark I, Bathurst Melinda A, Colombani Paul M, Casella James F, Nabaweesi Rosemary, Chang David C

机构信息

Division of Pediatric Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-0005, USA.

出版信息

Pediatr Blood Cancer. 2009 Jul;52(7):834-7. doi: 10.1002/pbc.21954.

Abstract

OBJECTIVE

The objective of the present study is to profile the outcome and safety of pediatric patients undergoing splenectomy with hereditary spherocytosis (HS) using a nationwide sample and the Agency for Healthcare Research and Quality (AHRQ) Pediatric Quality Indicators (PDIs).

PATIENTS AND METHODS

A retrospective cross-sectional descriptive analysis of a non-overlapping combination of the National Inpatient Sample (NIS), and Kids' Inpatient Database (KID) databases (1988-2004) were performed. These combined databases contain information from nearly 93 million discharges in the United States. Children with an age at admission of <18 years of age and HS (ICD-9 diagnosis code of 282.0) who underwent total splenectomy (ICD-9 procedure code of 41.5) were identified. Variables of gender, race, co-existing diagnoses, hospital type, and charges adjusted to 2006 dollars, length of stay, inpatient mortality, and complications were collected. PDIs were identified for each patient by linking the data obtained from the NIS and KID databases with the PDIs using the AHRQ Quality Indicators Wizard.

RESULTS

Splenectomy for HS was associated with low morbidity and mortality. Accompanying cholecystectomy and/or appendectomy appeared to be safely performed at the same operation. Of the 13 PDIs identified by AHRQ as potentially avoidable adverse events, none were observed to occur in more than 1% of the patients.

CONCLUSIONS

Based on the results of this study, splenectomy in patients with HS appears safe and to result in a minimal number of potentially preventable complications as identified by the AHRQ PDIs. We have successfully demonstrated use of the indicators to aid in the analysis of a specific surgical procedure within a subset of the pediatric population.

摘要

目的

本研究的目的是利用全国性样本以及医疗保健研究与质量局(AHRQ)的儿科质量指标(PDIs),剖析患有遗传性球形红细胞增多症(HS)的儿科患者接受脾切除术后的结局及安全性。

患者与方法

对国家住院样本(NIS)和儿童住院数据库(KID)数据库(1988 - 2004年)的非重叠组合进行回顾性横断面描述性分析。这些合并后的数据库包含了美国近9300万例出院病例的信息。确定了入院年龄小于18岁且患有HS(国际疾病分类第九版诊断代码为282.0)并接受全脾切除术(国际疾病分类第九版手术代码为41.5)的儿童。收集了性别、种族、并存诊断、医院类型、按2006年美元调整后的费用、住院时间、住院死亡率及并发症等变量。通过使用AHRQ质量指标向导将从NIS和KID数据库获得的数据与PDIs相链接,为每位患者确定PDIs。

结果

HS脾切除术的发病率和死亡率较低。同期进行胆囊切除术和/或阑尾切除术似乎可安全施行。在AHRQ确定为潜在可避免不良事件的13项PDIs中,未观察到超过1%的患者发生这些情况。

结论

基于本研究结果,HS患者的脾切除术似乎是安全的,且导致的AHRQ PDIs所确定的潜在可预防并发症数量最少。我们已成功证明利用这些指标有助于分析儿科人群亚组中的特定外科手术。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验